Press Releases Events & Presentations Press Releases Year None202120202019201820172016201520142013201220112010 Jun 09, 2021 Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021 View HTML PDF Version Jun 04, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version May 24, 2021 Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors View HTML PDF Version May 07, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version May 06, 2021 Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates View HTML PDF Version Mar 05, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Feb 26, 2021 Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus View HTML PDF Version Feb 25, 2021 Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights View HTML PDF Version Feb 25, 2021 Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection View HTML PDF Version Feb 19, 2021 Assembly Bio Announces Upcoming Investor Events View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds Search Investors
Press Releases Year None202120202019201820172016201520142013201220112010 Jun 09, 2021 Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021 View HTML PDF Version Jun 04, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version May 24, 2021 Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors View HTML PDF Version May 07, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version May 06, 2021 Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates View HTML PDF Version Mar 05, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View HTML PDF Version Feb 26, 2021 Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus View HTML PDF Version Feb 25, 2021 Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights View HTML PDF Version Feb 25, 2021 Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection View HTML PDF Version Feb 19, 2021 Assembly Bio Announces Upcoming Investor Events View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
